<- Go Home
PharmaSGP Holding SE
PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company’s pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil pharmaceutical drops for the treatment of nerve pain in neck and back; Revitensin, a drug for the treatment of hair loss; Dorisol for neuralgia (nerve pain), headaches, and migraines; Fulminan, a beauty drink; Lindaven, a pharmaceutical drops to treat their unpleasant problem; and SCLEROCALMAN, a drug for the treatment of clogged cerebral blood vessels. It also offers Prostacalman, a medication for cystitis and urination discomfort in a benign enlarged prostate; Revoten for women with weak connective tissue; Mindalin, a micronutrient drink for a healthy cardiovascular system; MELISTON, a prescription-free tablets to treat anxiety, restlessness, and mood swings; Deruba, a cream for skin redness; Lentisol that prevents the formation of new pigment spots; Neodolor, a headache tablet; DESEO pharmaceutical drops for sexual weakness; Neradin, a drug for sexual dysfunction; and TAUMEA, a drug for the treatment of vertigo. The company sells its products through pharmacies and wholesalers. It also exports its products to European countries comprising Austria, Italy, Belgium, Spain, and France. The company was founded in 2019 and is based in Gräfelfing, Germany.
Market Cap
EUR 379.9M
Volume
N/A
Cash and Equivalents
EUR 30.1M
EBITDA
EUR 36.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 114.4M
Profit Margin
90.45%
52 Week High
EUR 33.00
52 Week Low
EUR 28.40
Dividend
1.55%
Price / Book Value
9.69
Price / Earnings
20.24
Price / Tangible Book Value
-24.40
Enterprise Value
EUR 412.1M
Enterprise Value / EBITDA
11.29
Operating Income
EUR 27.2M
Return on Equity
52.68%
Return on Assets
13.64
Cash and Short Term Investments
EUR 30.1M
Debt
EUR 62.3M
Equity
EUR 39.2M
Revenue
EUR 126.4M
Unlevered FCF
EUR 6.7M
Sector
Pharmaceuticals
Category
N/A